SG11202006470RA - Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma - Google Patents
Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphomaInfo
- Publication number
- SG11202006470RA SG11202006470RA SG11202006470RA SG11202006470RA SG11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA
- Authority
- SG
- Singapore
- Prior art keywords
- pyridin
- fluoro
- methylsulfonimidoyl
- methoxyphenyl
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18156576 | 2018-02-13 | ||
| PCT/EP2019/053407 WO2019158517A1 (en) | 2018-02-13 | 2019-02-12 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006470RA true SG11202006470RA (en) | 2020-08-28 |
Family
ID=61223765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006470RA SG11202006470RA (en) | 2018-02-13 | 2019-02-12 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11701347B2 (en) |
| EP (1) | EP3752487A1 (en) |
| JP (1) | JP7280286B2 (en) |
| KR (1) | KR20200119800A (en) |
| CN (1) | CN111727183B (en) |
| AU (1) | AU2019221019A1 (en) |
| BR (1) | BR112020016389A2 (en) |
| CA (1) | CA3090843A1 (en) |
| CL (1) | CL2020002087A1 (en) |
| EA (1) | EA202091894A1 (en) |
| IL (1) | IL276437B2 (en) |
| JO (1) | JOP20200196A1 (en) |
| MA (1) | MA51820A (en) |
| MX (1) | MX2020008447A (en) |
| SG (1) | SG11202006470RA (en) |
| WO (1) | WO2019158517A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008447A (en) | 2018-02-13 | 2020-09-28 | Bayer Ag | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfo nimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
| EP1218360B1 (en) | 1999-10-07 | 2008-05-28 | Amgen Inc., | Triazine kinase inhibitors |
| CN1307173C (en) | 2000-12-21 | 2007-03-28 | 葛兰素集团有限公司 | Pyrimidineamines as angiogenesis modulators |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2003037346A1 (en) | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| ES2392426T3 (en) | 2002-07-18 | 2012-12-10 | Janssen Pharmaceutica Nv | Kinase inhibitors with substituted triazine |
| DE10239042A1 (en) | 2002-08-21 | 2004-03-04 | Schering Ag | New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
| WO2004072063A1 (en) | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| DE10349423A1 (en) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments |
| EP1799657B1 (en) | 2004-10-05 | 2009-12-02 | Syngenta Limited | Isoxazoline derivatives and their use as herbicides |
| MX2007007272A (en) | 2004-12-17 | 2007-07-11 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors. |
| DE102005062742A1 (en) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases |
| EP1803723A1 (en) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide derivatives as selective inhibitors of the aurora kinase for the treatment of cancer |
| JP4305477B2 (en) | 2006-07-25 | 2009-07-29 | トヨタ自動車株式会社 | Spark ignition internal combustion engine |
| DE102006041382A1 (en) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl sulfoximides as protein kinase inhibitors |
| DE102006042143A1 (en) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Novel substituted bipyridine derivatives and their use |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| CA2672518A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Organic compounds and their uses |
| US20100093776A1 (en) | 2006-12-22 | 2010-04-15 | Novartis Ag | Organic Compounds and Their Uses |
| BRPI0808888B8 (en) | 2007-03-12 | 2021-05-25 | Cytopia Res Pty Ltd | phenyl amino pyrimidine compound for use in the treatment of a kinase-associated disease, process for preparing the compound, pharmaceutical composition, and implant |
| WO2008129070A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| JP5379787B2 (en) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | Protein kinase inhibitors |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| ES2535166T3 (en) | 2007-09-04 | 2015-05-06 | The Scripps Research Institute | Substituted pyrimidinyl amines as protein kinase inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| AU2010291212A1 (en) | 2009-09-04 | 2012-02-23 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| NZ599826A (en) | 2009-10-12 | 2014-08-29 | Myrexis Inc | Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1 |
| US20130079345A1 (en) | 2010-03-22 | 2013-03-28 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| DE102010046720A1 (en) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Process for the preparation of pan-CDK inhibitors of the formula (I), as well as intermediates of the preparation |
| AU2011331161A1 (en) | 2010-11-17 | 2013-05-02 | Novartis Ag | 3-(aminoaryl)-pyridine compounds |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101065A2 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyrimidine biaryl amine compounds and their uses |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| WO2012101062A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
| US9226929B2 (en) | 2011-03-02 | 2016-01-05 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| CN103562184B (en) | 2011-03-02 | 2016-04-27 | 利德探索中心有限公司 | The Disubstituted pyridine derivatives of pharmaceutical active |
| EP2696683A4 (en) | 2011-04-12 | 2014-08-13 | Alzheimer S Inst Of America Inc | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
| CN102731413A (en) | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | Urea compound and its preparation method, intermediate and use |
| CA2833288A1 (en) | 2011-04-19 | 2012-10-26 | Bayer Intellectual Property Gmbh | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines |
| TW201636330A (en) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group |
| EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
| JP5982490B2 (en) | 2011-09-16 | 2016-08-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Disubstituted 5-fluoro-pyrimidine |
| CA2848615C (en) | 2011-09-16 | 2020-02-25 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| WO2014060376A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
| EP2920153B1 (en) | 2012-11-15 | 2017-02-01 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
| ES2612978T3 (en) * | 2012-11-15 | 2017-05-19 | Bayer Pharma Aktiengesellschaft | 5-Fluoro-n- (pyridin-2-yl) pyridin-2-amine derivatives containing a sulfoximin group |
| CA2917096C (en) | 2013-07-04 | 2021-05-18 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
| WO2015136028A1 (en) | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
| CN107427520A (en) | 2015-03-24 | 2017-12-01 | 拜耳医药股份有限公司 | The amine of 4 (methoxyphenyl of 4 fluorine 2) N { 3 [(S sulfonyloxy methyls imino group) methyl] phenyl } 1,3,5 triazine 2 is used for the purposes for treating lymthoma |
| MX2020008447A (en) | 2018-02-13 | 2020-09-28 | Bayer Ag | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfo nimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma. |
-
2019
- 2019-02-12 MX MX2020008447A patent/MX2020008447A/en unknown
- 2019-02-12 JO JOP/2020/0196A patent/JOP20200196A1/en unknown
- 2019-02-12 BR BR112020016389-9A patent/BR112020016389A2/en unknown
- 2019-02-12 KR KR1020207022928A patent/KR20200119800A/en unknown
- 2019-02-12 CA CA3090843A patent/CA3090843A1/en active Pending
- 2019-02-12 WO PCT/EP2019/053407 patent/WO2019158517A1/en unknown
- 2019-02-12 SG SG11202006470RA patent/SG11202006470RA/en unknown
- 2019-02-12 MA MA051820A patent/MA51820A/en unknown
- 2019-02-12 EP EP19704618.8A patent/EP3752487A1/en active Pending
- 2019-02-12 EA EA202091894A patent/EA202091894A1/en unknown
- 2019-02-12 AU AU2019221019A patent/AU2019221019A1/en active Pending
- 2019-02-12 US US16/969,460 patent/US11701347B2/en active Active
- 2019-02-12 JP JP2020565543A patent/JP7280286B2/en active Active
- 2019-02-12 IL IL276437A patent/IL276437B2/en unknown
- 2019-02-12 CN CN201980013294.2A patent/CN111727183B/en active Active
-
2020
- 2020-08-12 CL CL2020002087A patent/CL2020002087A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111727183B (en) | 2023-12-29 |
| EA202091894A1 (en) | 2020-12-28 |
| MA51820A (en) | 2021-05-19 |
| AU2019221019A1 (en) | 2020-07-23 |
| JOP20200196A1 (en) | 2020-08-13 |
| BR112020016389A2 (en) | 2020-12-15 |
| CN111727183A (en) | 2020-09-29 |
| IL276437B2 (en) | 2024-03-01 |
| CA3090843A1 (en) | 2019-08-22 |
| JP7280286B2 (en) | 2023-05-23 |
| US20210015806A1 (en) | 2021-01-21 |
| US11701347B2 (en) | 2023-07-18 |
| MX2020008447A (en) | 2020-09-28 |
| CL2020002087A1 (en) | 2020-12-11 |
| EP3752487A1 (en) | 2020-12-23 |
| JP2021514386A (en) | 2021-06-10 |
| IL276437B1 (en) | 2023-11-01 |
| KR20200119800A (en) | 2020-10-20 |
| WO2019158517A1 (en) | 2019-08-22 |
| IL276437A (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281597A (en) | Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use | |
| SG11202001503SA (en) | Axisymmetric adjustable device for treating mitral regurgitation | |
| IL287145A (en) | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| IL280123A (en) | Compounds and methods for reducing atxn2 expression | |
| IL250715B (en) | A composition comprising a 3-(3-(4-1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or a derivative thereof for use in the treatment of cell proliferative disorder | |
| KR102116867B9 (en) | Surface treatment device for implant | |
| ZA202002517B (en) | Compounds and methods for reducing snca expression | |
| EP3122360A4 (en) | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma | |
| DK3490625T3 (en) | Device with structured coating for use as an implant for the treatment of perforations in the eardrum | |
| SI3962601T1 (en) | 5-ht2a agonists for use in treatment of depression | |
| SG11202009171XA (en) | Surface treatment method of wafer and composition used for said method | |
| IL276437A (en) | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma | |
| IL285546A (en) | Compounds and methods for reducing kcnt1 expression | |
| IL277238A (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| EP3442015A4 (en) | Wafer holding mechanism and method for rotary table and rotary wafer holding device | |
| EP3836936A4 (en) | Treatment of relapsed follicular lymphoma | |
| IL288900A (en) | Treatment comprising fxr agonists | |
| EP3740328A4 (en) | Multipurpose machine for surface treatment and related method | |
| DK4036095T3 (en) | 4-FLUORO-1H-PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES AS SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA AND AUTOIMMUNE DISEASES | |
| IL275384A (en) | Methods and compositions for pre-emptive treatment of graft versus host disease | |
| ZA202007320B (en) | Compounds for pain treatment, compositions comprising same, and methods of using same | |
| MX2020005557A (en) | Fxr agonists for the treatment of liver diseases. | |
| IL283054A (en) | Methods of treating myelodysplastic syndrome | |
| IL276576A (en) | Therapeutic agents for treating restless legs syndrome |